Bromocriptine-Induced Changes in Hormone Secretion and Cell Morphology in Growth Hormone and Prolactin Producing Pituitary Adenomas

References

• Adams E. F., Brajkovich I. E., Mashiter K. Hormone secretion by dispersed cell cultures of human pituitary adenomas: effects of theophylline. thyreotro-pin releasing hormone. somatomedin and 2-bromo- -ergocriptine. J Clin Endocr Metab 1979; 49: 120
   PubMedGoogle Scholar
• Anniko M., Eneroth P., Werner S., Wersäll J. In vitro preservation of human pituitary tumours in organotypic differentiation. Acta Otolaryngol (Stockh) 1979; 88: 424
   PubMed Web of Science ®Google Scholar
• Arnoff S. L., Bangladay W. H., Laws E. K. Bromocriptine treatment of prolactinomas. N Engl J Med 1979; 300: 1391
   Google Scholar
• Bergh T., Nillius S. J., Wide L. Hyperprolactinaemic amenorrhoea—results of treatment with bromocriptine. Acta endocrinol (Kbh) 1978; 88: 147
   Google Scholar
• Bergh T., Nillius S. J., Lundberg P. O., Wide L. Bromocriptine treatment of prolactinomas. N Engl J Med 1979; 300: 1391
   PubMedGoogle Scholar
• Besser G. M., Parkes L., Edwards C. K. W., Forsyth L. A., McNeilly A. S. Galactorrhoea: Successful treatment with reduction of plasma prolactin levels by Bromergocyptine. Brit Med J 1972; iii: 669
   Google Scholar
• Besser G. M., Wass J. A. H., Thorner M. O. Actomegaly. Results of long term treatment with bromocriptine. Acta Endocrinol (Kbh) 1978; 88: 187
   Google Scholar
• Camanni F., Massard F., Belforte L., Molinathi G. M. Changes in plasma growth hormone levels in normal and acromegalic subjects following administration of 2-Br-2-ergocriptine. J Clin Endocr 1975; 70: 363
   Google Scholar
• Cassar J., Mashiter K., Joplin G. F. Bromocriptine treatment of acromegaly. Metabolism 1977; 26: 539
   PubMed Web of Science ®Google Scholar
• Farquhar M. G. Lysosome function in regulating secretion: disproval of secretory granules in cells of the anterior pituitary gland. Lysosomes in Biology and Pathology, Bingle, Fell. North-Holland Publishing Co. 1969; Vol. 2: 462–482
   Google Scholar
• Fluckiger E. The pharmacology of bromocriptine. Pharcological and Clinical Aspects of Bromocriptine (Parlodel), R. I. S. Bayliss, P. Turner, W. F. Maclay. Tunbridge Wells, KentUK 1976; 12–26
   Google Scholar
• Fluckiger E. Effects of bromocriptine on the hypothalamopituitary axis. Acta Endocirnol (Kbh) 1978; 88: 111
   Google Scholar
• Flückiger E., Del Pozo E. Influence on the endocrine system. Ergot Alkaloids and Similar Compounds. Handbook of Experimental Pharmacology, B. Berde, H. O. Schild. Springer-Verlag. 1978; vol. 51, (in press).
   Google Scholar
• Fossati P., Stranch G., Tournaire J. Etude de l'activité de la bromocriptine dans les états d'hyper-prolactinémie. Nouv Presse Méd 1976; 5: 1687
   PubMedGoogle Scholar
• Lamberts S. W. J., Klijn J. G. M., Kwa G. H., Birkenhäger J. C. The dynamics of growth hormone and prolactin secretion in acromegalic patients with mixed pituitary tumours. Acta Endocrinol (Kbh) 1979; 90: 198
   PubMedGoogle Scholar
• Landolt A. M., Wüthrick R., Fellman H. Regression of pituitary prolactinoma after treatment with bromocriptine. Lancet 1979; i(8125)1082
   Google Scholar
• Liuzzi A., Clinoidini P. G., Botalla L., Cremascoli G., Müller E. E., Silverstini F. Decreased plasma growth hormone (GH) levels in acromegalics following CB 154 (2-Br-2-ergocryptine) administration. J Clin Endocr Metab 1974; 38: 910
   PubMed Web of Science ®Google Scholar
• Lloyd H. M., Meares J. D., Jacob J. Effects of oestrogen and bromocriptine on in vitro secretion and mitosis in prolactin cells. Nahne 1975; 255: 497
   Google Scholar
• Mashiter K., Adams E., Beard M., Halley A. Bromocriptine inhibits prolactin and growth hormone release by human pituitary tumours in culture. Lancet 1977; ii: 197
   Google Scholar
• McGregor A. M., Scanlon M. F., Hall K., Cook D. B., Hall R. Reduction in size of a pituitary tumour by bromocriptine therapy. N Engl J Med 1979; 300: 291
   PubMed Web of Science ®Google Scholar
• Mühlenstedt D., Osmers F., Schneider H. P. G. Regression eines Hypophysenadenoma enter Bromo-criptin. Arch Gynecol 1978; 226: 341
   PubMedGoogle Scholar
• Rolland R., Schellekens L. A., Lequin R. M. Successful treatment of galactorrhoea and amenorrhoea and subsequent restoration of ovarian function by a new ergot alkalvid, 2-Br-2-ergocryptine. Clin Endocr 1974; 3: 155
   PubMedGoogle Scholar
• Thorner M. O., Besser G. M., Hagen C., McNeilly A. S. Long term treatment of galactorrhoea and hypogonadism with bromocriptine. Brit Med J 1974; ii: 419
   Google Scholar
• Thorner M. O., Besser G. M., Jones A., Dacie J., Jones A. E. Bromocriptine therapy of female infertility—a report of thirteen pregnancies. Brit Med J 1975; iv: 694
   Google Scholar
• Tramu G., Beauvillain J. C., Mazzuca M., Grenier J. L., Fossati P., Christiaeurs J. C. Time dependent evolution of pituitary prolactin adenoma, under bromocriptine therapy. Congress on bromocriptine therapy (abstract). 2nd European Workshop on Pituitary Adenomas, Paris 1979; 87
   Google Scholar
• Varga L., Lutterbeck P. M., Pryor J. S., Wenner R., Erb H. Suppression of puerperal lactation with an ergot alkaloid. Brit Med J 1972; ii: 743
   Google Scholar
• Wass J. A. H., Moult P. J. A., Thorner M. O., Dacie J. E., Charlesworth M., Jones A. E., Besser G. M. Reduction of pituitary tumour six in patient with prolactionomas and acromegaly treated with bromocriptine with or without radiotherapy. Lancet 1979; ii: 66, (8133)
   Google Scholar
• von Werder K., Eversmann T., Fahlbusch K., Rjosk H. K. Bromocriptine treatment of prolactino-mas.N. Engl J Med 1979; 300: 1391
   PubMedGoogle Scholar
• Werner S., Hall K., Sjöberg H. E. Bromocriptine therapy in patients with acromegaly: effects on growth hormone. somatomedin A and prolactin. Acta Endocrinol (Kbh) 1978; 88: 199
   PubMedGoogle Scholar